Bendazac

Bendazac is an oxyacetic acid with anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties. Bendazac acts by preventing protein denaturation and delays the cataractogenic process. Bendazac exerts funciton in anti-radical effect and inhibits oxidative brust[1][2][3].

Product Specifications

CAS Number

[20187-55-7]

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bendazac.html

Purity

99.92

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(O)COC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3

Molecular Formula

C16H14N2O3

Molecular Weight

282.29

Precautions

H302, H312, H332

References & Citations

[1]Balfour JA, et al. Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs. 1990;39 (4) :575-596.|[2]Guglielmotti A, et al. Radical scavenger activity of bendazac, an anticataract non-steroidal anti-inflammatory agent. Pharmacol Res. 1995;32 (6) :369-373.|[3]Musci G, et al. Mechanism of the scavenger-like activity of bendazac. Drugs Exp Clin Res. 1987;13 (5) :289-292.|[4]Guglielmotti A, et al. Anti-radical effects and oxidative burst inhibition of bendazac, an anticataract nonsteroidal antiinflammatory agent[J]. Pharmacological Research, 1995, 31: 360.